Updates

FDA has approved single-dose booster for children ages 5-11

On May 17, 2022, the U.S. Food and Drug Administration authorized the use of a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age at least five months after completing a primary series with the Pfizer-BioNTech COVID-19 vaccine. (See the FDA announcement.) The Centers for Disease Control and Prevention approved the booster for this age group on May 19, 2022. CDC now recommends that children ages 5 through 11 years should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series. (See the CDC announcement.)

The booster shot is 10 micrograms, the same dosage as the primary series for this age group and a third of the dosage given to people 12 and older.

The FDA has determined that the known and potential benefits of this single booster dose outweigh its known and potential risks and that a booster dose can help provide continued protection against COVID-19 in this and older age groups.

Vaccination continues to be the most effective way to prevent COVID-19 and its severe consequences, and it is safe.

If your child is eligible for the Pfizer-BioNTech COVID-19 vaccine and has not yet received their primary series, getting them vaccinated can help protect them from the potentially severe consequences of the disease, such as hospitalization and death.

COVID-19 vaccines can be scheduled at UTMB online or via MyChart.

Thank you.

Janak Patel, MD
Director, UTMB Infection Control and Healthcare Epidemiology
Professor, Pediatrics/Infectious Disease

Philip Keiser, MD
Professor, UTMB Internal Medicine/Infectious Diseases
Galveston County Health Authority
UTMB COVID-19 Vaccination Preparedness Task Force Chair

 

Photo of Pfizer COVID Vaccine bottle